22/01/2026
๐
๐๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐ ๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐ ๐๐๐๐๐๐๐๐ ๐๐๐
๐๐๐ ๐
๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐
The Food and Drug Administration (FDA) advises the public on the status of reports received in relation to the ongoing voluntary recall of specific batches of NAN OPTIPRO and NANKID OPTIPRO infant formula products, as indicated in FDA Advisory 2026-0030.
As of 15 January 2026, the FDA has received twenty-five (25) reports associated with the recalled products. Eighteen (18) of these reports involve health concerns observed by parents or caregivers following consumption of the subject infant formula. Reported symptoms include vomiting, diarrhea, abdominal pain, and other conditions, some of which required medical attention.
All reports received by the FDA are subject to review to determine the appropriate regulatory actions. Each report is evaluated, andโwhen necessaryโthe FDA coordinates with relevant agencies and offices to ensure proper handling, verification, and resolution of the reported concerns.
The FDA continues to maintain close regulatory coordination with the Market Authorization Holder, Nestlรฉ Philippines, Inc., which has been directed to submit regular and timely status reports on the implementation, assessment, and progress of the voluntary recall. Established procedures remain in place for the receipt, documentation, assessment, and appropriate disposition of consumer complaints, including reports of suspected adverse events. The FDA continues to exercise regulatory oversight of the recall through the review of information submitted by relevant parties and the conduct of post-market surveillance.
The FDA understands the concerns of parents and caregivers and encourages them to continue closely caring for and observing the well-being of their infants and young children. Should there be any concerns about a childโs health, seeking advice from a healthcare professional is encouraged. To help the FDA monitor the situation and provide appropriate assistance, parents and caregivers may also report any related concerns through ereport@fda.gov.ph.
The FDA remains committed to safeguarding public health, particularly the health and safety of infants and young children. Further information will be communicated as warranted, consistent with verified findings and established regulatory processes.
